Skip to main content

Recent HIV testing and self-reported HIV prevalence among men who inject drugs in Afghanistan: a nationwide survey in 2019–2020

Abstract

Background

People who inject drugs (PWID) remain at high risk for HIV in many countries, including Afghanistan. Previous reports on HIV testing and prevalence in Afghanistan were published in 2012. This study assessed recent HIV testing and self-reported HIV prevalence among male PWID in Afghanistan from 2019 to 2020.

Method

We visited 374 public venues and hotpots where PWID used to gather and meet their peers across 8 cities in Afghanistan to enroll eligible participants in our study. Using interviews and a survey, our trained interviewers collected data on the demographics, types of drugs, HIV testing history, and self-reported HIV status of the participants. We analyzed the data using the venues and hotpots as clusters to report the percentages of recent HIV tests and self-reported HIV prevalence overall and in subgroups defined by demographic characteristics and locations.

Results

Among the 1385 participants, most were from Kabul city (28.9%), spoke Dari (67.4%), were aged 25–34 years (42.1%), and were married (52.4%). Overall, 70.7% (95% CI 67.6–73.6) (ranging from 20.0% in Kandahar to 99.3% in Mazar-i-Sharif) were tested for HIV within the past 12 months. Among those who had ever been tested for HIV, 20.7% (95% CI 17.8–24.0) (ranging from 0% in Zarang to 63.2% in Kabul) reported being positive for HIV.

Conclusion

Compared with the results of a similar study in 2012, we found a significant improvement in HIV testing coverage among PWID in Afghanistan. The high self-reported HIV prevalence among this group also highlights the need for targeted screening and treatment programs for PWID in Afghanistan, particularly in the cities of Kabul and Jalalabad.

Introduction

The updated data for HIV and AIDS are limited in Afghanistan. As of 2023, UNAIDS estimates 13,000 (4200–54000) adults and children living with HIV in Afghanistan, with an estimated 1700 (< 500–9200) new infections per year. It is estimated that only 3300 people living with HIV know their HIV status [1].

People who inject drugs (PWID) continue to be at high risk for HIV in many countries, including Afghanistan. Using multiple methods of population size estimation, we estimated 11,506 PWID in 8 study cities and projected approximately 57,000 PWID in Afghanistan [2]. The latest reported HIV prevalence among PWID was 4.4% among PWID in 2012. The prevalence of HIV among PWID varies significantly across cities: 1.0% in Mazar-i-Sharif, 3.1% in Kabul, 18.4% in Herat [3] 0.3% in Mazar, 0.9% in Charikar, 1.0% in Jalalabad, 2.4% in Kabul and 13.3% in Herat [4].

HIV testing plays a crucial role in preventing HIV transmission. Among PWID, preventing HIV is one of the most cost-effective strategies [5]. HIV testing and counseling allow people at risk to make informed decisions to start HIV treatment and to engage more in prevention measures [6, 7]. To break the chain of transmission, early HIV diagnosis is also critical [8]. A previous study among PWID in Kabul was conducted in 2012, when only 2.7% of PWID had ever been tested for HIV [4].

Voluntary Counselling and Testing Centers, HIV care and ART are offered in five provinces (Kabul, Herat, Mazar, Nangarhar and Khost) in Afghanistan [9]. HIV diagnosis in Afghanistan follows the national guideline using three consecutive rapid tests. Those testing positive on all three are referred to antiretroviral therapy (ART) centers, where a confirmatory rapid test is conducted before starting treatment. Only confirmed positive cases receive ART. Since 2016, Afghanistan has implemented a “test and treat” strategy, initiating (ART for all confirmed HIV-positive patients regardless of CD4 count or disease stage.

The most recent data on HIV testing and prevalence among people who inject drugs (PWID) in Afghanistan came from a 2012 survey, more than a decade old. In our study, we examined recent HIV testing and the prevalence of self-reported HIV among male PWID in Afghanistan during 2019–2020. Additionally, we analyzed the associations between various covariates and both recent HIV testing and self-reported HIV prevalence among this population.

Methods

We analyzed the data that were collected in a cross-sectional survey from 2019 to 2020. The study locations included eight cities (Kabul, Herat, Mazar-I-Sharif, Jalalabad, Kunduz, Faizabad, Kandahar, and Zaranj) to provide relatively representative cross-sections of the regions of Afghanistan. Eligible PWID were anyone aged 18 years and older who had injected any type of drug at least once for nonmedical purposes in the past 12 months. We found only 9 female PWIDs, so the current analysis focused only on male PWIDs (excluding women because of the very small sample size). All participants provided verbal informed consent via procedures approved by the Institutional Review Boards (IRBs) of the Afghanistan National Public Health Institute, Ministry of Public Health (#444899, 12/29/2018), and the University of California San Francisco (#234207, 03/08/2019).

We applied venue-based purposive sampling to enroll PWID. We used key informant mapping to identify locations (venues) where PWID congregate, the days and times they frequent these spots. A total of 217 individuals, including representatives from NGOs, government officials, health authorities, DIC staff, and current or former PWID, were interviewed individually or in focus group discussions. Key informants from across the city identified hotspots, and peak activity hours. Then study staff were trained in a 3-day workshop to conduct interviews and collect data on demographics, drug use behaviors, HIV testing, and HIV self-reported test results. Field supervisors monitored data collection daily, and team leads provided weekly oversight. The details of the study design were presented previously [2].

The data were collected through a structured data collection form. The first part of the form included screening questions assessing the participants’ eligibility, followed by demographic and drug-related questions. Furthermore, the form contained questions about risk behaviors, HIV testing history, and self-reported HIV infection status.

We analyzed the data for two primary outcomes. The first outcome, HIV testing, was categorized as an ordinal variable with three levels: tested within the last 12 months, tested more than 12 months ago, and never tested. For further analysis, we created a binary outcome for recent HIV testing, classifying participants as either having been tested in the last 12 months (yes) or not (no). The second outcome focused on HIV self-reported status among individuals who had ever been tested for HIV, creating a binary variable to distinguish between those who self-reported as HIV-positive and those who reported being HIV-negative (yes/no). Of the participants who had ever been tested for HIV, 172 (15.1%) did not disclose their HIV status; these individuals were excluded from the analysis of self-reported HIV status.

We analyzed the associations between various covariates and both HIV testing and self-reported HIV prevalence using separate bivariable and multivariable logistic regression models to identify significant predictors while adjusting for potential confounders. In the bivariable analyses, each covariate was individually tested for its association with HIV testing and self-reported HIV prevalence, by chi-saure test and by simple logistic regression providing unadjusted odds ratios (ORs). In the multivariable logistic regression models, we included all covariates to estimate adjusted odds ratios (AORs), controlling for the effects of other variables and ensuring robust results. The covariates included in the analyses were the city of study, language spoken (as a proxy for regional and cultural background), age, and marital status. Substance use variables included heroin use, cocaine use, opium use, amphetamine use, and prescribed drug use. Additional covariates were the time of injection (e.g., daytime vs. nighttime) and sexual behaviors, specifically ever having oral or anal sex with other men. These factors were chosen based on their relevance to HIV transmission and testing behaviors, as well as prior evidence in the literature.

Results

We analyzed the data of 1385 male PWID (Table 1). Most of the participants were from Kabul city (28.9%), spoke Dari (67.4%), were aged 25–34 years (42.1%) and were married (52.4%). Almost all (99.4%) reported using heroin in the previous month. Most participants (72.9%) reported their last injection to be in the previous month, whereas 3.8% reported engaging in oral or anal sex with other men in their lifetime.

Table 1 Demographics and risk behaviors of men who inject drugs in urban cities in Afghanistan from 2019–2020, n = 1385

Among the 1385 male PWID, 70.7% had been tested within the last 12 months, 11.3% had been tested more than 12 months prior, and 18% had never been tested for HIV. The proportion of HIV testing within the last 12 months ranged from 20.0% in Kandahar to 99.3% in Mazar-i-Sharif. The proportion of recent HIV tests within the last 12 months was significantly lower in those who spoke Pashto (65.3%) and those who used opium (37.7%) than in their counterparts (Table 2).

Table 2 HIV testing history by demographics and risk behaviors of men who inject drugs in Afghanistan, n = 1385

Among those who had ever been tested for HIV (1136), 964 reported their HIV status (172 or 15.1% had missing data on self-reported HIV status). Among those 964 individuals who reported their HIV status (Table 3), 20.7% reported having HIV-positive results in the past. The self-reported HIV prevalence ranged from 0% in Zarang to 27.1% in Jalalabad and 63.2% in Kabul. The prevalence of self-reported HIV was significantly greater among male PWID who spoke Pashto (26.5%), were aged 35–44 years (27.1%), were married and lived with their partner (29.6%), did not use opium in the previous month (21.4%), used amphetamine or methamphetamine (37.3%), and reported injection in the previous month (25.6%) than among their counterparts.

Table 3 The prevalence of self-reported HIV status by demographics and risk behaviors of men who inject drugs, Afghanistan, n = 964

In the multivariable logistic regression analysis for recent HIV tests (Table 4), those PWID who lived at Herat ([Adjusted Odds Ratio] AOR = 2.35; 95% CI: 1.22–4.54), Mazar-i-sharif (AOR = 71.13; 95% CI: 9.35–541.10), Jalalabad (AOR = 42.19; 95% CI: 5.20–342.61), Faizabad (AOR = 12.74; 95% CI: 2.84–57.18) has a higher odds for being tested for HIV recently. While those who lived in Kandahar (AOR = 0.17; 95% CI: 0.08–0.38) [vs. those in Kabul], those injected with opium last month (AOR = 0.38; 95% CI: 0.17–0.88) [vs. not injecting opium during the last month], those injected within the last 12 months (AOR = 0.46; 95% CI: 0.27–0.77) [vs. those injected within the last month], and those who had ever had oral or anal sex with another man (AOR = 0.40; 95% CI 0.20–0.78) has a lower odds for being tested for HIV recently.

Table 4 Bivariate and multivariable logistic regression analysis of factors associated with recent HIV tests of men who inject drugs in Afghanistan

In the multivariable logistic regression analysis for HIV self-report status (Table 5), PWID who lived in Herat (AOR = 0.03; 95% CI: 0.01–0.13) Mazar-i-sharif (AOR = 0.01; 95% CI: 0.00-0.03), Jalalabad (AOR = 0.05; 95% CI: 0.01–0.19), Kunduz (AOR = 0.01; 95% CI: 0.00-0.04) and Kandahar (AOR = 0.03; 95% CI: 0.01–0.05) [vs. those in Kabul]; spoke Dari (AOR = 0.36; 95% CI: 0.15–0.88) [vs. Pashto]; and were injected with opium last month (AOR = 0.13; 95% CI: 0.04–0.51) [vs. not injecting opium during the last month]; and were injected within the last 12 months (AOR = 0.28; 95% CI: 0.09–0.90) [vs. those injected within the last month] has a lower odds for being self-reported HIV positive.

Table 5 Bivariable and multivariable logistic regression analysis of factors associated with self-reported HIV-positive status of men who inject drugs, Afghanistan

Discussion

Our results revealed that approximately 70% of male PWID had been tested for HIV in the last 12 months before the survey. Compared with previous studies (2012), HIV testing coverage has increased significantly across several cities in Afghanistan. However, HIV testing was significantly lower among male PWID living in Kabul and Kandahar and among those who injected opium and those who reported having sex with other men. These areas and subpopulations should be prioritized for more targeted HIV testing campaigns or programs.

Another important finding of our study was that among those male PWID who had ever been tested for HIV, one in five reported a positive HIV test result. While a direct comparison of our finding on self-reported HIV prevalence to those results from the previous study (2012) is not possible, our findings suggested an increase in the HIV prevalence (from 4.4% in 2012 to 20.7% in 2019-20) among male PWID. The HIV prevalence estimates in our study (2019-20) were based on self-reported data, which may partly reflect improvements in HIV coverage and case-finding efforts. Additionally, those who lived in Kabul, spoke Pashto, were married/lived with a partner, aged 35–44 years, used amphetamine or methamphetamine, and were injecting drugs in the previous month had a significantly higher self-reported HIV prevalence and should be targeted for HIV diagnosis and linkage to anti-retroviral therapy (ART) services. Past studies of PWID in Kabul [3, 4] also reported a high prevalence of shared injection (33.6%), having bought sex from female sex workers (66%), having sex with another male (28%), and a high frequency of unsafe sex (66%) in 2009, a high frequency of injection (82.6%), and having been injected more than one year (56.3%) in 2012. Additionally, certain groups of male PWID, such as those who speak Pashto and those who actively inject drugs (reported their last injection during the month before the survey), had higher self-reported HIV prevalence. Screening and linkage to treatment for these groups can help them access and start HIV treatment. Language spoken may serve as a proxy for geographic origin or residence, potentially indicating regional differences in self-reported HIV prevalence, access to testing, awareness, and health service utilization. In our study, individuals from certain regions who spoke Uzbek might face higher vulnerability due to variations in HIV epidemic dynamics, stigma, or health system capacity for HIV testing and care.

We found that HIV testing among male PWID has increased significantly since the last study in Afghanistan in 2012. Using respondent driving sampling, a previous survey in 2012 in Afghanistan revealed that a much lower number of PWID had ever been tested for HIV [4]. Over several years, interventions such as the expansion of HIV testing sites [10], the addition of rapid HIV tests to needle and exchange programs [11], peer support [12], the leveraging of social networks to disseminate messages on HIV awareness [12, 13], the increase in awareness of HIV and the importance of HIV testing, especially among those at high risk, such as PWID [13], have led to improvements in the coverage of HIV testing programs in Afghanistan. However, there are still certain areas, such as Kanda, and certain subgroups, such as those who use opium, need to be targeted for HIV programs, as they have lower HIV testing rates. Partnerships with trusted community leaders through community-based interventions, such as home-based self-testing, mobile outreach, and hybrid approaches, can improve HIV testing in low-resource settings among priority populations, resulting in increased HIV testing [14].

Venue-based sampling, though commonly used for hard-to-reach populations like PWID, has inherent limitations that may introduce selection bias. It captures only individuals present at specific venues during sampling periods, excluding those who avoid these spaces due to stigma or other factors, leading to underrepresentation of certain subgroups. Additionally, sampling times may not reflect the diversity of the population, and individuals who frequent venues more often may differ in risk profiles or behaviors. These biases can affect the generalizability of our findings, particularly HIV prevalence estimates. Studies with responded-driven sampling [15] that enrolled PWID via networks or other novel sampling methods such as starfish sampling that combined venues and network enrolment strategies [16] can be useful to see if there was such a selection bias affected our findings.

Our study has three main limitations. First, we measured the HIV prevalence via self-reports among those who had ever been tested for HIV in the past; it is possible that some people did not report the truth about their HIV status (most likely not disclosing that they were HIV positive) or that their status has changed since the time they were tested for HIV. These factors might have resulted in an underestimation of the true HIV prevalence. Second, the participants in our study were recruited from several locations where PWID used to gather and see their peers; thus, we did not enroll those who did not visit such venues in our study. Finally, owing to changes in the health system and governance in Afghanistan and the COVID-19 disruption of services, our data on HIV testing and prevalence may not reflect the current situation in Afghanistan. A new survey of PWID is needed to obtain an updated situation and results.

Despite these limitations, our multicity study revealed some progress in HIV testing among one of the key populations, male PWID, at high risk for HIV in Afghanistan. The high self-reported HIV prevalence among this group also highlights the need for targeted screening and treatment programs for this group in several cities in Afghanistan. Targeted interventions such as expanding harm reduction services among this population can reduce the risk of HIV transmission among PWID in Afghanistan.

Data availability

The datasets used and/or analyzed in the current study are available from the corresponding author upon reasonable request.

References

  1. UNAIDS. UNAIDS Country factsheets: Afghanistan [Internet]. [cited 2024 Dec 6]. Available from: https://www.unaids.org/en/regionscountries/countries/afghanistan

  2. Rasheed A, Sharifi H, Wesson P, Pashtoon SJ, Tavakoli F, Ghalekhani N, et al. Mapping and population size estimates of people who inject drugs in Afghanistan in 2019: synthesis of multiple methods. PLoS ONE. 2022;17:e0262405.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Ruiseñor-Escudero H, Wirtz AL, Berry M, Mfochive-Njindan I, Paikan F, Yousufi HA, et al. Risky behavior and correlates of HIV and hepatitis C virus infection among people who inject drugs in three cities in Afghanistan. Drug Alcohol Depend. 2014;143:127–33.

    Article  PubMed  Google Scholar 

  4. Johns Hopkins Bloomberg School of Public Health, National AIDS Control Program - MoPH of Islamic Republic of Afghanistan. Integrated Behavioral & Biological Surveillance (IBBS) in Afghanistan,Findings of 2012 IBBS survey and comparison to 2009 IBBS survey. 2012.

  5. Venkatesh KK, Becker JE, Kumarasamy N, Nakamura YM, Mayer KH, Losina E, et al. Clinical impact and cost-effectiveness of expanded voluntary HIV testing in India. PLoS ONE. 2013;8:e64604.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. WHO EMRO| HIV testing. and counselling| About| AIDS and sexually transmitted diseases [Internet]. [cited 2024 Dec 6]. Available from: https://www.emro.who.int/asd/about/testing-counselling.html

  7. Kapadia F, Landers S. Ending the HIV epidemic: getting to zero AND staying at zero. Am J Public Health. 2020;110:15–6.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Mohammadi Y, Mirzaei M, Shirmohammadi-Khorram N, Farhadian M. Identifying risk factors for late HIV diagnosis and survival analysis of people living with HIV/AIDS in Iran (1987–2016). BMC Infect Dis. 2021;21:390.

    Article  PubMed  PubMed Central  Google Scholar 

  9. AFG_2019_countryreport.pdf [Internet]. [cited 2024 Dec 6]. Available from: https://www.unaids.org/sites/default/files/country/documents/AFG_2019_countryreport.pdf

  10. Trayner KMA, Palmateer NE, McAuley A, Metcalfe R, Goldberg DJ, Peters E, et al. Evaluation of the scale-up of HIV testing among people who inject drugs in Scotland in the context of an ongoing HIV outbreak. Int J Drug Policy. 2021;96:103304.

    Article  PubMed  Google Scholar 

  11. El-Bassel N, McCrimmon T, Wu E, Chang M, Terlikbayeva A, Hunt T, et al. Effectiveness of an intervention to improve HIV service delivery for people who inject drugs in Kazakhstan: A cluster trial. JAMA Netw Open. 2022;5:e2244734.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Iryawan AR, Stoicescu C, Sjahrial F, Nio K, Dominich A. The impact of peer support on testing, linkage to and engagement in HIV care for people who inject drugs in Indonesia: qualitative perspectives from a community-led study. Harm Reduct J. 2022;19:16.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Detsis M, Tsioutis C, Karageorgos SA, Sideroglou T, Hatzakis A, Mylonakis E. Factors associated with HIV testing and HIV treatment adherence: A systematic review. Curr Pharm Des. 2017;23:2568–78.

    Article  CAS  PubMed  Google Scholar 

  14. Sundararajan R, Ponticiello M, Nansera D, Jeremiah K, Muyindike W. Interventions to increase HIV testing uptake in global settings. Curr HIV/AIDS Rep. 2022;19:184–93.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Raifman S, DeVost MA, Digitale JC, Chen Y-H, Morris MD. Respondent-Driven Sampling: a Sampling Method for Hard-to-Reach Populations and Beyond. Current Epidemiology Reports [Internet]. 2022;9:38–47. Available from: https://doiorg.publicaciones.saludcastillayleon.es/10.1007/s40471-022-00287-8

  16. Raymond HF, Chen Y-H, McFarland W. Starfish sampling: a novel, hybrid approach to recruiting hidden populations. J Urban Health. 2019;96:55–62.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We thank the people who participated in this study. We acknowledge the support of the Afghanistan Ministry of Public Health, the National AIDS Control Program, and harm reduction organizations. We also appreciate the data collectors, provincial supervisors, data management offices, and IT, administrative, and logistical support teams. Finally, we thank the ITAPS mentorship and H2R training programs for their support and mentorship.

Funding

This work was supported by the Global Fund to Fight AIDS, Tuberculosis, and Malaria (UNDP/AFG/GS/2018/084– Recipient: Ali Mirzazadeh) and the National Institute of Mental Health (5R25MH129290). The lead author (AS) also received support from the University of California, San Francisco’s International Traineeships in AIDS Prevention Studies (ITAPS), U.S. NIMH, R25MH064712. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The views and opinions expressed herein are those of the individual authors and not necessarily those of their institutes or funders.

Author information

Authors and Affiliations

Authors

Contributions

Ajmal Sabawoon performed the literature review and data analysis and wrote the original draft. Ali Mirzazadeh led the whole process and coordinated the activities. Similarly, Sima Naderi, Said Iftekhar Sadat, Abdul Rasheed, Fatemeh Tavakoli and Hamid Sharifi reviewed the manuscript critically and provided feedback to enrich the content.

Corresponding author

Correspondence to Ali Mirzazadeh.

Ethics declarations

Ethical approval and consent to participate

All participants provided verbal informed consent via procedures approved by the Institutional Review Boards (IRBs) of the Afghanistan National Public Health Institute, Ministry of Public Health (#444899, 12/29/2018), and the University of California San Francisco (#234207, 03/08/2019).

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sabawoon, A., Naderi, S., Sadaat, S.I. et al. Recent HIV testing and self-reported HIV prevalence among men who inject drugs in Afghanistan: a nationwide survey in 2019–2020. Harm Reduct J 22, 31 (2025). https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s12954-025-01183-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s12954-025-01183-2

Keywords